Targeted integration enables predictable clonal cell lines, enhancing transgene control and accelerating biopharma cell line development.
Hang Zhou
Advertisement
Hang Zhou, PhD, is head of Bioprocess Research & Development, WuXi Biologics.
Articles by Hang Zhou
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
2
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
4
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
5